Smarter. Stronger. Together: Educating Providers and Patients to Optimize the Use of Targeted Oral Therapies for HR+/HER2- Breast Cancer

Download All

Gain perspectives on strategies for optimizing use of CDK4/6 and PI3K inhibitors for HR+/HER2- breast cancer, including discussion on effective patient education about these targeted oral therapies! Learn from the experts with downloadable slides, commentaries, podcast, on-demand Webcast, and an Interactive Decision Support Tool providing personalized management recommendations for adverse events associated with CDK4/6 and PI3K inhibitors.

Resources for your patients: https://www.smartpatients.com/resources/cco-breast-cancer

Donna M. Fitzgerald, PA-C, MPAS
Matthew P. Goetz, MD
Marissa Marti, APRN, AGNP-C, AOCNP
Joyce O'Shaughnessy, MD
Laura M. Spring, MD

Interactive Decision Support Tool

Use this Interactive Decision Support Tool to learn strategies to assess and manage adverse events associated with oral targeted therapy for HR-positive, HER2-negative breast cancer from 5 experts.

Donna M. Fitzgerald, PA-C, MPAS Matthew P. Goetz, MD Marissa Marti, APRN, AGNP-C, AOCNP Joyce O'Shaughnessy, MD Laura M. Spring, MD Released: September 14, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue